Categories Analysis, Earnings, U.S. Markets News
Strong earnings help Wall Street tide over Octoberphobia declines
October is one month that terrifies investors, thanks to its notorious past. Historically, this month has been the most volatile and has triggered the biggest sell-offs on multiple occasions including 1929 crash as well as the infamous 2008 financial crisis.
This October, it was no different in terms of volatility and stock sell-offs. So far, there have already been three trading days when the S&P 500 index recorded more than 1% single-day declines.
Hurt by last week’s sell-offs, as on Monday, Dow Jones Industrial Average was down 4.2%, while the S&P 500 index had declined about 5% in October. Nasdaq witnessed the biggest month-to-date fall of 6.8%.
While Octoberphobia seemed once again tightening its clutches, all it took for Wall Street to break free was a single day of market-beating quarterly results. Led by outperforming stocks including Goldman Sachs (GS) and United Health Group (UNH), the Dow Jones Industrial Average gained 276 points as markets opened on Tuesday. The Nasdaq Composite and S&P 500 also reacted positively, gaining 1.4% and 1% respectively.
UNH shares jumped 4% during morning trade after the company posted better-than-expected results and raised full-year outlook. America’s fifth largest bank by assets, Goldman Sachs (GS), meanwhile, reported a 25% increase in earnings, sending its shares up 1.8% during morning trade.
Other major companies, Morgan Stanley (MS) and Johnson & Johnson (JNJ) also provided enough backing. While Morgan Stanely is up 4.5% at 11:30AM ET, JNJ has risen 1.65%.
Investors are now closely watching Netflix (NFLX), which is scheduled to report earnings aftermarket today. If the streaming giant manages to surprise the Wall Street with its third-quarter results, and also buck speculations that further steady growth is impossible in user base, it would provide further relief to Octoberphobia concerns.
Most Popular
Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO
Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training
INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues
Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came
Riding the AI wave, Nvidia looks set to stay on the high-growth path
After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on